Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Loddenkemper

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
MMW Fortschritte Der Medizin|March 8, 2017
Robert Loddenkemper
Deutsches Arzteblatt International|January 22, 2010
Drug-resistant tuberculosis: a worldwide epidemic poses a new challengeRobert Loddenkemper, Barbara Hauer
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|April 18, 2012
Treatment of MDR-TB: is hepatotoxicity a problem?Robert Loddenkemper, Tom Schaberg
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|December 13, 2012
Prolonged isoniazid prevention in HIV-positive children: hepatotoxicity is not a major problemRobert Loddenkemper, Roland Diel
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|June 5, 2018
Insufficient pharmacological research on TB drugs: new insights on safety are neededGiovanni Sotgiu, Robert Loddenkemper
Deutsches Arzteblatt International|March 23, 2010
Rare pathologiesBarbara Hauer, Robert Loddenkemper
Chest|May 15, 2007
Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in GermanyRoland Diel, Albert Nienhaus, Robert Loddenkemper
Anticancer Research|May 25, 2004
Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: phase II trialMonika Serke, Nikolas Schoenfeld, Robert Loddenkemper
Chest|December 22, 2009
Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysisRoland Diel, Robert Loddenkemper, Albert Nienhaus
Chest|April 12, 2012
Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysisRoland Diel, Robert Loddenkemper, Albert Nienhaus
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
MMW Fortschritte Der Medizin|March 8, 2017
Robert Loddenkemper
Deutsches Arzteblatt International|January 22, 2010
Drug-resistant tuberculosis: a worldwide epidemic poses a new challengeRobert Loddenkemper, Barbara Hauer
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|April 18, 2012
Treatment of MDR-TB: is hepatotoxicity a problem?Robert Loddenkemper, Tom Schaberg
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|December 13, 2012
Prolonged isoniazid prevention in HIV-positive children: hepatotoxicity is not a major problemRobert Loddenkemper, Roland Diel
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|June 5, 2018
Insufficient pharmacological research on TB drugs: new insights on safety are neededGiovanni Sotgiu, Robert Loddenkemper
Deutsches Arzteblatt International|March 23, 2010
Rare pathologiesBarbara Hauer, Robert Loddenkemper
Chest|May 15, 2007
Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in GermanyRoland Diel, Albert Nienhaus, Robert Loddenkemper
Anticancer Research|May 25, 2004
Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: phase II trialMonika Serke, Nikolas Schoenfeld, Robert Loddenkemper
Chest|December 22, 2009
Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysisRoland Diel, Robert Loddenkemper, Albert Nienhaus
Chest|April 12, 2012
Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysisRoland Diel, Robert Loddenkemper, Albert Nienhaus
Pageof 4